Generex Biotechnology Corporation (OTCMKTS:GNBT) is a Canada-based Company, which develops drug delivery systems and technologies for the treatment of diabetes. The Company has developed a proprietary platform technology for the delivery of drugs into the human body through the oral cavity. Its buccal insulin spray product, Generex Oral-lyn is in Phase III clinical trials at several sites around the world. Generex Biotechnology Corporation (OTCMKTS:GNBT) stock opened at $0.06 in last trading session, and closed at $0.0450, trading in the range of $0.05 – $0.06. The stock showed a positive weekly performance of 12.50%.
ThermoGenesis Corp (NASDAQ:KOOL) announced that it has entered into definitive agreements with institutional investors in connection with a private placement of common stock and warrants to purchase common stock. Upon the closing of this financing, ThermoGenesis will receive gross proceeds of approximately $6.67 million resulting from the issuance and sale of approximately 3.33M shares of common stock at a price per share of $2.00. The purchasers will also receive warrants to purchase up to approximately 1.66M shares of common stock at an exercise price of $2.81 per share. The warrants are non-exercisable for six months after the closing of the financing and have a term of 5 years. ThermoGenesis Corp (NASDAQ:KOOL) shares closed at $2.45 on last trade day, by losing -13.12%. Stock 52 week range is $0.71 – $3.24. Company’s market capitalization is $40.86 billion.
TheStreet Quant Ratings rates Sirona Dental Systems, Inc. (NASDAQ:SIRO) as a buy. The company’s strengths can be seen in multiple areas, such as its revenue growth, largely solid financial position with reasonable debt levels by most measures, increase in net income, growth in earnings per share and expanding profit margins. We feel these strengths outweigh the fact that the company has had somewhat disappointing return on equity. Sirona Dental Systems, Inc. (NASDAQ:SIRO) stock surged 3.35% and finished the last session at $75.19. The EPS of the stock remained 2.61. Company’s market capitalization is $4.14 billion.
Celsion Corporation (NASDAQ:CLSN) said Monday it wants to start another late-stage clinical trial of its liver cancer drug ThermoDox. The company said a year ago that ThermoDox did not meet its main goal in a clinical trial because it didn’t improve their time to death or disease progression. Celsion said it is still following patients from that trial and said some may be living longer. Celsion Corporation (NASDAQ:CLSN) stock opened at $4.00 in last trading session and closed at $3.76. The 52 week range of the stock is $3.38 – $38.03 and the day range was $3.65 – $4.03.
Leave a Reply